Guardion Health Sciences Announces Clinical Results Indicating that Viactiv® Omega Boost™ Gel Bites Increase Omega-3 Levels in Just 4 weeks
October 06 2022 - 8:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), a clinical nutrition company that offers a
portfolio of science-based, clinically supported products designed
to support the health needs of consumers, healthcare professions
and providers and their patients, announces interim four-week
results of a clinical study designed to evaluate the effectiveness
of new Viactiv Omega Boost Gel Bites at increasing Omega-3
saturation levels on red blood cells. The 1,200 mg Omega-3 gel
bites contain both DHA and EPA and are designed to provide total
body support, including cardiovascular, brain, immune and eye
health.
The new gel bite dosage form provides the potency of large,
hard-to-swallow soft gels, in a great tasting chewable format that
has more than ten times the amount of Omega-3s than the leading
omega-3 gummy. The gel bite delivery has no sugar and no unpleasant
fishy aftertaste.
“Our interim clinical results showed a 51% improvement in
Omega-3 levels in just 4 weeks which exceeded our expectations,”
commented Bret Scholtes, Guardion’s Chief Executive Officer.
“Although Viactiv Omega Boost is positioned at a more premium price
point, it is a better value for our consumers because it is proven
to work. The amount of high-quality Omega-3s in a supplement does
matter, and this product reflects Guardion’s continuing commitment
to deliver science-based, clinically supported product that can
make a difference in the health of our customers.”
Viactiv Omega Boost™ is available for sale at
www.viactiv.com
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical
nutrition company that offers a portfolio of science-based,
clinically supported products designed to support the health needs
of consumers, healthcare professionals and providers and their
patients. The Company’s combination of expertise and scientifically
supported products is the foundation of Guardion’s growing position
within the clinical nutrition marketplace. Information and risk
factors with respect to Guardion and its business may be obtained
in the Company’s filings with the SEC at www.sec.gov.
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in
this news release, the matters described herein may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements contain information about our expectations, beliefs,
plans or intentions regarding our product development and
commercialization efforts, research and development efforts,
business, financial condition, results of operations, strategies or
prospects, and other similar matters. Statements preceded by,
followed by or that otherwise include the words “believes,”
“expects,” “anticipates,” “intends,” “projects,” “estimates,”
“plans,” “hopes” and similar expressions or future or conditional
verbs such as “will,” “should,” “would,” “may” and “could” are
generally forward-looking in nature and not historical facts,
although not all forward-looking statements include the foregoing.
These statements are based on management’s current expectations and
assumptions about future events, which are inherently subject to
uncertainties, risks and changes in circumstances that are
difficult to predict, and involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
raise sufficient financing to implement its business plan, the
integration of new management team members, the implementation of
new financial, management, accounting and business software
systems, the integration of the Viactiv acquisition and possibly
additional acquisition targets, the impact of the Covid-19
pandemic, supply chain disruptions, inflation and a potential
recession on the Company’s business, operations and the economy in
general, the Company’s ability to successfully develop and
commercialize its proprietary products and technologies, and the
Company’s ability to maintain compliance with Nasdaq’s listing
requirements. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations Contact:CORE IRScott
Arnold516-222-2560scotta@coreir.com
Media Relations Contact:Jules AbrahamDirector
of Public RelationsCORE IR917-885-7378julesa@coreir.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024